Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Candel Therapeutics Inc (CADL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/17/2025: CADL (3-star) is a STRONG-BUY. BUY since 4 days. Profits (7.62%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $22
1 Year Target Price $22
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 339.61% | Avg. Invested days 35 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 07/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 343.20M USD | Price to earnings Ratio - | 1Y Target Price 22 |
Price to earnings Ratio - | 1Y Target Price 22 | ||
Volume (30-day avg) 3 | Beta -0.87 | 52 Weeks Range 3.79 - 13.68 | Updated Date 07/17/2025 |
52 Weeks Range 3.79 - 13.68 | Updated Date 07/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.33 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -32.31% | Return on Equity (TTM) -98.14% |
Valuation
Trailing PE - | Forward PE 43.48 | Enterprise Value 261951351 | Price to Sales(TTM) 436.42 |
Enterprise Value 261951351 | Price to Sales(TTM) 436.42 | ||
Enterprise Value to Revenue 821.98 | Enterprise Value to EBITDA -0.01 | Shares Outstanding 50102700 | Shares Floating 40685880 |
Shares Outstanding 50102700 | Shares Floating 40685880 | ||
Percent Insiders 17.53 | Percent Institutions 40.72 |
Upturn AI SWOT
Candel Therapeutics Inc
Company Overview
History and Background
Candel Therapeutics, Inc. (CADL) is a late clinical-stage biopharmaceutical company focused on developing oncolytic viral immunotherapies to stimulate the patient's immune system against cancer. Founded in 2003, it has evolved from preclinical research to clinical trials, primarily focused on its two platforms: enGeneIC delivery system and oncolytic viral immunotherapy.
Core Business Areas
- Oncolytic Viral Immunotherapy: Developing oncolytic viral immunotherapies using genetically engineered viruses to selectively infect and destroy cancer cells, while stimulating an immune response against the tumor.
Leadership and Structure
Dr. Paul Peter Tak serves as the CEO. The company has a structured management team overseeing research and development, clinical operations, and corporate strategy.
Top Products and Market Share
Key Offerings
- CAN-2409: An off-the-shelf adenovirus, CAN-2409, to induce an individualized, systemic anti-tumor immune response through in situ vaccination. Currently in clinical trials for non-small cell lung cancer, pancreatic cancer, and other solid tumors. Competitors include companies developing similar oncolytic viral therapies, such as Replimune (REPL), Oncolytics Biotech (ONCY), and Turnstone Biologics (TSBX).
Market Dynamics
Industry Overview
The oncolytic virus immunotherapy market is growing, driven by the potential to improve cancer treatment outcomes by harnessing the patient's immune system. Increased research funding and regulatory support are contributing to market expansion.
Positioning
Candel Therapeutics is positioned as a clinical-stage company focused on advancing its oncolytic viral immunotherapy platform, with CAN-2409 as its lead product candidate. The company aims to differentiate itself through its technology and clinical trial outcomes.
Total Addressable Market (TAM)
The TAM for oncolytic virus therapy is expected to reach billions of dollars. Candel's positioning focuses on specific cancer types where its therapies may offer a clinical advantage.
Upturn SWOT Analysis
Strengths
- Proprietary oncolytic viral immunotherapy platform
- Promising clinical trial data for CAN-2409
- Experienced management team
Weaknesses
- Limited financial resources relative to larger pharmaceutical companies
- Reliance on successful clinical trial outcomes
- High regulatory hurdles and development risks
Opportunities
- Positive clinical trial results leading to regulatory approval and commercialization
- Partnerships and collaborations with larger pharmaceutical companies
- Expansion into new cancer indications
Threats
- Clinical trial failures
- Competition from other cancer therapies
- Regulatory setbacks
- Difficulties in raising capital
Competitors and Market Share
Key Competitors
- REPL
- ONCY
- TSBX
Competitive Landscape
Candel faces intense competition from companies with approved or late-stage oncolytic virus therapies. Success hinges on demonstrating superior efficacy and safety in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited due to being a clinical-stage company.
Future Projections: Future growth depends on the successful development and commercialization of CAN-2409. Analyst estimates vary depending on clinical trial outcomes.
Recent Initiatives: Focus on advancing CAN-2409 through clinical trials, including Phase 2 and Phase 3 studies. Actively seeking collaboration opportunities.
Summary
Candel Therapeutics is a clinical-stage biopharmaceutical company with a promising oncolytic viral immunotherapy platform. Its success depends on positive clinical trial results and successful commercialization of CAN-2409. Key challenges include competition, regulatory hurdles, and securing sufficient funding. While its pipeline is promising, the company's financial stability and reliance on successful clinical outcomes represent significant risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Candel Therapeutics Inc. SEC Filings
- Candel Therapeutics Inc. Investor Relations
- Industry Reports on Oncolytic Virus Immunotherapy
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market data is based on estimates and may not be precise. Investment decisions should be based on your own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Candel Therapeutics Inc
Exchange NASDAQ | Headquaters Needham, MA, United States | ||
IPO Launch date 2021-07-27 | President, CEO & Director Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 38 | Website https://www.candeltx.com |
Full time employees 38 | Website https://www.candeltx.com | ||
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the"enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.